

| Company | Total Program Liability | PY2 Orders* | Rollover to PY3 | Total Remaining Liability | Total Remaining Liability as a % of Total Program Liability |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|--------------|-----------------|---------------------------|-------------------------------------------------------------|
| Original Settlement Companies | | | | | |
| AHP* | \$ 16,053,300 | \$ 5,234,992 | \$ 4,272,102 | \$ 9,623,202 | 59.95% |
| Dupont | \$ 2,773,198 | \$ 544,469 | \$ 733,574 | \$ 1,657,973 | 59.79% |
| Rhone-Poulenc Rorer* | \$ 2,968,493 | \$ 738,339 | \$ 549,852 | \$ 1,539,350 | 51.86% |
| Merck | \$ 19,568,621 | \$ 5,300,532 | \$ 2,204,448 | \$ 8,727,322 | 44.60% |
| Abbott | \$ 5,155,804 | \$ 1,879,758 | \$ 553,542 | \$ 2,272,143 | 44.07% |
| Upjohn | \$ 9,999,136 | \$ 2,855,758 | \$ 1,070,335 | \$ 4,403,380 | 44.04% |
| SmithKline Beecham* | \$ 11,209,969 | \$ 2,633,318 | \$ 1,164,705 | \$ 4,901,361 | 43.72% |
| Bristol-Myers Squibb | \$ 12,811,393 | \$ 5,255,818 | \$ 1,042,020 | \$ 5,312,485 | 41.47% |
| Zeneca* | \$ 5,819,809 | \$ 1,503,246 | \$ 306,200 | \$ 2,246,136 | 38.59% |
| Boehringer-Ingelheim* | \$ 2,519,314 | \$ 988,697 | \$ 96,410 | \$ 936,181 | 37.16% |
| Glaxo-Wellcome | \$ 19,392,855 | \$ 5,299,256 | \$ 315,940 | \$ 6,780,225 | 34.96% |
| Eli Lilly | \$ 11,913,033 | \$ 3,889,571 | \$ 81,440 | \$ 4,052,451 | 34.02% |
| Pfizer | \$ 11,795,856 | \$ 4,133,433 | \$ 62,413 | \$ 3,994,365 | 33.86% |
| Carter Wallace | \$ 705,675 | \$ 238,290 | \$ 2,896 | \$ 238,121 | 33.74% |
| Warner Lambert | \$ 5,702,632 | \$ 1,804,902 | \$ 16,026 | \$ 1,916,903 | 33.61% |
| Schering-Plough* | \$ 8,339,123 | \$ 3,475,940 | \$ 8,304 | \$ 2,788,012 | 33.43% |
| Knoll | \$ 1,367,069 | \$ 492,208 | \$ 11 | \$ 455,701 | 33.33% |
| TOTAL | \$ 148,095,280 | | | \$ 61,845,310 | |
| Second Settlement Companies | | | | | |
| Searle* | \$ 2,441,000 | \$ 531,889 | \$ 1,909,111 | \$ 1,909,111 | 78.21% |
| Hoechst-Marion Rousse | \$ 6,366,500 | \$ 2,002,210 | \$ 4,364,290 | \$ 4,364,290 | 68.55% |
| Novartis* | \$ 7,431,000 | \$ 2,660,901 | \$ 4,770,099 | \$ 4,770,099 | 64.19% |
| Ortho-McNeil * | \$ 2,998,500 | \$ 2,748,507 | \$ 249,993 | \$ 249,993 | 8.34% |
| Roche | \$ 1,962,500 | \$ 1,860,132 | \$ 102,368 | \$ 102,368 | 5.22% |
| Janssen* | \$ 1,858,000 | \$ 1,857,913 | \$ 87 | \$ 87 | 0.00% |
| TOTAL | \$ 23,057,500 | | | \$ 11,395,948 | |
| TOTAL BOTH SETTLEMENT GROUPS | \$ 171,152,780 | | | \$ 73,241,258 | |
| *Each PY2 Order figure has been confirmed by the company, except for companies that have not responded by April 29, 2002 to requests for review and confirmation | | | | | |